Gilead Sciences completed its acquisition of Arcellx, Inc. on April 28, 2026, for an aggregate transaction value of approximately $7.1 billion. Shareholders received $115.00 per share in cash plus one contingent value right (CVR) worth $5.00, which is payable if cumulative worldwide sales of the anito-cel product exceed $6.0 billion by December 31, 2029.
